REGENXBIO's Duchenne Gene Therapy Hits Primary Endpoint, Eyes 2027 Approval
Event summary
- REGENXBIO's RGX-202 achieved 93% microdystrophin expression in Phase III AFFINITY DUCHENNE trial (p<0.0001).
- Statistically significant correlation between microdystrophin expression and functional improvement observed.
- Company preparing for potential accelerated FDA approval in 2027.
- Trial enrolled 31 ambulatory boys aged 1 year and older, with dosing completion expected by mid-2026.
The big picture
REGENXBIO's positive Phase III results position RGX-202 as a potential best-in-class gene therapy for Duchenne Muscular Dystrophy, addressing a critical unmet need in rare disease treatment. The statistically significant correlation between microdystrophin expression and functional improvement strengthens the case for accelerated approval, though regulatory flexibility remains a key variable. The company's differentiated approach, including a novel construct and proactive immune suppression regimen, could set a new standard in gene therapy safety and efficacy.
What we're watching
- Regulatory Pathway
- Whether FDA will accept externally controlled trials for substantial evidence of effectiveness.
- Competitive Positioning
- How RGX-202's differentiated construct and safety profile compare to Novartis' Zolgensma.
- Commercialization Timing
- The pace at which REGENXBIO can prepare for a potential 2027 launch.
Related topics